CD274 and neoplasm: It functions primarily by binding to the PD-1 receptor, blocking the interaction between PD-1 and PD-L1/PD-L2, thereby inhibiting immune escape by tumor cells and exerting an antitumor effect.[14] Anlotinib is a novel multitarget tyrosine kinase inhibitor used to inhibit VEGFR2/3, FGFR1–4, and PDGFRα/β, among others.